Turner Syndrome and Neurofibromatosis 1
Rare Co-Existence with Important Clinical Implications
DOI:
https://doi.org/10.15605/jafes.038.01.20Keywords:
Turner syndrome, Neurofibromatosis 1, NF-1, Neurofibromatosis-Noonan syndromeAbstract
A 16.5-year-old Indian female presented with secondary amenorrhoea, cubitus valgus, scoliosis and multiple lentigines on the face. Karyotyping revealed mosaic Turner syndrome (TS) with 45, X/46, X iXq. She also had multiple café-au-lait macules and axillary freckles but no neurofibroma and did not fulfil the classic criteria for diagnosis of Neurofibromatosis-1(NF1). Many of her macules were smaller than 15 mm in diameter, which might be due to her hypoestrogenic state. However, exome-sequencing found a pathologic variant consistent with NF1. She was started on daily oral estrogen, and oral progesterone for 10 days every month with close monitoring for neurofibroma and/or glioma expansion. Co-occurrence of NF1 and TS is extremely rare, TS and NF1 can both affect growth and puberty, cause different cutaneous and skeletal deformities, hypertension, vasculopathy and learning disabilities. Our case highlights the need for genetic testing in some cases with NF1 who do not strictly fulfil the NIH diagnostic criteria. We also emphasize the need for close monitoring during therapy with growth hormone, estrogen and progesterone due to the potential risk of tumour expansion in NF1.
Downloads
References
Schorry E, Lovell A, Milatovich A, Saal H. Ullrich-Turner syndrome and neurofibroma-tosis. Am J Med Genet. 1996;66(4):423-5. https://pubmed.ncbi.nlm.nih.gov/ 8989459. https://doi.org/10.1002/(SICI)1096-8628(19961230)66:4<423::AID-AJMG6>3.0.CO;2-L.
Suttur MS, Mysore SR, Krishnamurthy B, Nallur RB. Rare association of Turner syn-drome with neurofibromatosis type 1 and tuberous sclerosis complex. Indian J Hum Genet. 2009;15(2):75. https://pubmed.ncbi.nlm.nih.gov/ 20680156. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2910953. https://doi.org/10.4103/0971-6866.55220.
Hatipoglu N, Kurtoglu S, Kendirci M, Keskin M, Per H. Neurofibromatosis type 1 with overlap Turner syndrome and Klinefelter syndrome. J Trop Pediatr. 2010;56(1):69-72. https://pubmed.ncbi.nlm.nih.gov/19578129. https://doi.org/10.1093/tropej/fmp053.
Gengel N, Marshall I. Rare presentation of neurofibromatosis and Turner syndrome in a pediatric patient. Pediatr Rep. 2017;9(2):6810. https://pubmed.ncbi.nlm.nih.gov/28706617. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5494441. https://doi.org/10.4081/pr.2017.6810.
Khadilkar VV, Khadilkar AV. Revised Indian Academy of Pediatrics 2015 growth charts for height, weight and body mass index for 5–18-year-old Indian children. Indian J En-docrinol Metab. 2015;19(4):470-6. https://pubmed.ncbi.nlm.nih.gov/26180761. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4481652. https://doi.org/10.4103/2230-8210.159028.
Eichenfield LF, Levy ML, Paller AS, Riccardi VM. Guidelines of care for neurofibroma-tosis type 1. American Academy of Dermatology Guidelines/Outcomes Committee. J Am Acad Dermatol. 1997;37(4):625-30. https://pubmed.ncbi.nlm.nih.gov/9344204. https://doi.org/10.1016/s0190-9622(97)70182-8.
Sybert VP, McCauley E. Turner's syndrome. N Engl J Med. 2004;351(12):1227-38. https://pubmed.ncbi.nlm.nih.gov/15371580. https://doi.org/10.1056/NEJMra030360.
Gravholt CH, Backeljauw P. New international Turner syndrome guideline: A multi-society feat. Eur J Endocrinol. 2017;177(3): E1-2. https://pubmed.ncbi.nlm.nih.gov/28705802. https://doi.org/10.1530/EJE-17-0540.
Shen MH, Harper PS, Upadhyaya M. Molecular genetics of neurofibromatosis type 1 (NF1). J Med Genet. 1996;33(1):2-17. https://pubmed.ncbi.nlm.nih.gov/8825042. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1051805. https://doi.org/10.1136/jmg.33.1.2.
Williams VC, Lucas J, Babcock MA, Gutmann DH, Korf B, Maria BL. Neurofibromato-sis type 1 revisited. Paediatrics. 2009;123(1):124-33. https://pubmed.ncbi.nlm.nih.gov/19117870. https://doi.org/10.1542/peds.2007-3204.
Mondal S, Bhattacharjee R, Chowdhury S, Mukhopadhyay S. Heterogeneity of karyo-types in Turner Syndrome. Indian J Pediatr. 2021;88(2):175. https://pubmed.ncbi.nlm.nih.gov/32623591. https://doi.org/10.1007/s12098-020-03410-z.
Bizzarri C, Bottaro G. Endocrine implications of neurofibromatosis 1 in childhood. Horm Res Paediatr. 2015;83(4):232-41. https://pubmed.ncbi.nlm.nih.gov/25659607. https://doi.org/10.1159/000369802.
Mondal S, Bhattacharjee R, Chowdhury S, Mukhopadhyay S. Karyotype-Phenotype Cor-relation in Turner Syndrome at a Single Center in Eastern India. Indian Pediatr. 2021;58(1):34-7. https://pubmed.ncbi.nlm.nih.gov/33452775.
Martin DD, Schweizer R, Schwarze CP, Elmlinger MW, Ranke MB, Binder G. The early dehydroepiandrosterone sulfate rise of adrenarche and the delay of pubarche indicate primary ovarian failure in Turner syndrome. J Clin Endocrinol Metab. 2004;89(3):1164-8. https://pubmed.ncbi.nlm.nih.gov/15001603. https://doi.org/10.1210/jc.2003-031700.
Boulanger JM, Larbrisseau A. Neurofibromatosis type 1 in a pediatric population: Ste-Justine's experience. Can J Neurol Sci. 2005;32(2):225-31. https://pubmed.ncbi.nlm.nih.gov/16018159. https://doi.org/10.1017/s0317167100004017.
Cunha KSG, Barboza EP, da Fonseca EC. Identification of growth hormone receptor in plexiform neurofibromas of patients with neurofibromatosis type 1. Clinics (Sao Paulo). 2008;63(1):39-42. https://pubmed.ncbi.nlm.nih.gov/18297205. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2664176. https://doi.org/10.1590/s1807-59322008000100008.
Farid M, Demicco EG, Garcia R, et al. Malignant peripheral nerve sheath tumors. On-cologist. 2014;19(2):193-201. https://pubmed.ncbi.nlm.nih.gov/24470531. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3926794. https://doi.org/10.1634/theoncologist.2013-0328.
Howell SJ, Wilton P, Lindberg A, Shalet SM. Growth hormone and neurofibromatosis. Horm Res. 2000;53(Suppl 1):70-6. https://pubmed.ncbi.nlm.nih.gov/10895046. https://doi.org/10.1159/000053208.
Dugoff L, Sujansky E. Neurofibromatosis type 1 and pregnancy. Am J Med Genet. 1996;66(1):7-10. https://pubmed.ncbi.nlm.nih.gov/8957502. https://doi.org/10.1002/(SICI)1096-8628(19961202)66:1<7::AID-AJMG2>3.0.CO;2-R.
Posma E, Aalbers R, Kurniawan YS, Van Essen AJ, Peeters PMJG, Van Loon AJ. Neuro-fibromatosis type I and pregnancy: a fatal attraction? Development of malignant schwannoma during pregnancy in a patient with neurofibromatosis type I. BJOG. 2003;110(5):530-2. https://pubmed.ncbi.nlm.nih.gov/12742342.
Dagalakis U, Lodish M, Dombi E, et al. Puberty and plexiform neurofibroma tumor growth in patients with neurofibromatosis type I. J Pediatr. 2014;164(3):620-4. https://pubmed.ncbi.nlm.nih.gov/24321536 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3943976. https://doi.org/10.1016/j.jpeds.2013.10.081.
Diggs‐Andrews KA, Brown JA, Gianino SM, Rubin JB, Wozniak DF, Gutmann DH. Sex is a major determinant of neuronal dysfunction in neurofibromatosis type 1. Ann Neurol. 2014;75(2):309-16. https://pubmed.ncbi.nlm.nih.gov/24375753. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4172335. https://doi.org/10.1002/ana.24093.
Warrington NM, Sun T, Luo J, et al. The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients. Cancer Res. 2015;75(1):16–21. https://pubmed.ncbi.nlm.nih.gov/25381154. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4286430. https://doi.org/10.1158/0008-5472.CAN-14-1891.
Toonen JA, Solga AC, Ma Y, Gutmann DH. Estrogen activation of microglia underlies the sexually dimorphic differences in Nf1 optic glioma-induced retinal pathology. J Exp Med. 2017;214(1):17–25. https://pubmed.ncbi.nlm.nih.gov/27923908. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5206494. https://doi.org/10.1084/jem.20160447.
Henning AM, Handrup MM, Kjeldsen SM, Larsen DA, Ejerskov C. Optic pathway glio-ma and the sex association in neurofibromatosis type 1: A single-center study. Orphanet J Rare Dis. 2021;16(1):489. https://pubmed.ncbi.nlm.nih.gov/34809690. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8607578. https://doi.org/10.1186/s13023-021-02121-8.
Geller M, Mezitis SGE, Nunes FP, et al. Progesterone and estrogen receptors in neurofi-bromas of patients with NF1. Clin Med. Pathology. 2008;1:93-7. https://pubmed.ncbi.nlm.nih.gov/21876657. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160005. https://doi.org/10.4137/cpath.s1002.
Rozza-de-Menezes RE, Almeida LM, Andrade-Losso RM, et al. A Clinicopathologic Study on the role of estrogen, progesterone, and their classical and nonclassical recep-tors in cutaneous neurofibromas of individuals with neurofibromatosis 1. Am J Clin Pathol. 2021;155(5):738-47. https://pubmed.ncbi.nlm.nih.gov/33289020. https://doi.org/10.1093/ajcp/aqaa186.
Lammert M, Mautner VF, Kluwe L. Do hormonal contraceptives stimulate growth of neurofibromas? A survey on 59 NF1 patients. BMC Cancer. 2005;5:16. https://pubmed.ncbi.nlm.nih.gov/15703081. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC549555. https://doi.org/10.1186/1471-2407-5-16.
Xu J, Ismat FA, Wang T, Yang J, Epstein JA. NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response. Circulation. 2007;116(19):2148-56. https://pubmed.ncbi.nlm.nih.gov/17967772. https://doi.org/10.1161/CIRCULATIONAHA.107.707752.
Veean S, Thakkar N, Gupta S, Keshavamurthy J. A case of coarctation of the abdominal aorta and renal artery stenosis due to neurofibromatosis type 1. Postgrad Med J. 2017;93(1098):235-6. https://pubmed.ncbi.nlm.nih.gov/27708004. https://doi.org/10.1136/postgradmedj-2016-134460.
Allanson, JE, Hall, JG, Van Allen, MI. Noonan phenotype associated with neurofibroma-tosis. Am J Med Genet. 1985;21(3):457-62. https://pubmed.ncbi.nlm.nih.gov/2411134. https://doi.org/10.1002/ajmg.1320210307.
Pacheco TR, Oreskovich N, Fain P. Genetic heterogeneity in the multiple lentigi-nes/LEOPARD/Noonan syndromes. Am J Med Genet A. 2004;127(3):324-6. https://pubmed.ncbi.nlm.nih.gov/15150790. https://doi.org/10.1002/ajmg.a.20591.
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Dr Sunetra Mondal, Dr Neha Agrawal, Prof Dr Subhankar Chowdhury
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Journal of the ASEAN Federation of Endocrine Societies is licensed under a Creative Commons Attribution-NonCommercial 4.0 International. (full license at this link: http://creativecommons.org/licenses/by-nc/3.0/legalcode).
To obtain permission to translate/reproduce or download articles or use images FOR COMMERCIAL REUSE/BUSINESS PURPOSES from the Journal of the ASEAN Federation of Endocrine Societies, kindly fill in the Permission Request for Use of Copyrighted Material and return as PDF file to jafes@asia.com or jafes.editor@gmail.com.
A written agreement shall be emailed to the requester should permission be granted.
